BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26265439)

  • 21. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.
    Bueso-Ramos CE; Ferrajoli A; Medeiros LJ; Keating MJ; Estrov Z
    Hematology; 2004 Aug; 9(4):279-86. PubMed ID: 15621735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium signaling and cell fate: how can Ca2+ signals contribute to wrong decisions for Chronic Lymphocytic Leukemic B lymphocyte outcome?
    Debant M; Hemon P; Brigaudeau C; Renaudineau Y; Mignen O
    Int J Dev Biol; 2015; 59(7-9):379-89. PubMed ID: 26679951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
    Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
    Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
    Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
    Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential control of G0 programme in chronic lymphocytic leukaemia: a novel prognostic factor.
    Danilov AV; Klein AK; Lee HJ; Baez DV; Huber BT
    Br J Haematol; 2005 Feb; 128(4):472-81. PubMed ID: 15686454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Notch signal pathway and chronic lymphocytic leukemia].
    Zhang JY; Xu ZS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1472-5. PubMed ID: 25338610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
    Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
    Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
    Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
    Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL).
    Masood A; Shahshahan MA; Jazirehi AR
    Curr Drug Deliv; 2012 Jan; 9(1):30-40. PubMed ID: 22023214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.
    Ringshausen I; Peschel C; Decker T
    Leuk Lymphoma; 2005 Jan; 46(1):11-9. PubMed ID: 15621776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q; Bianchi P; Bezwoda WR
    Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
    Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
    Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
    Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
    Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C
    Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.
    Darwiche W; Gomila C; Ouled-Haddou H; Naudot M; Doualle C; Morel P; Nguyen-Khac F; Garçon L; Marolleau JP; Ghamlouch H
    J Exp Clin Cancer Res; 2020 Oct; 39(1):228. PubMed ID: 33115525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.
    Zhou K; Zhang W; Zhang Q; Gui R; Zhao H; Chai X; Li Y; Wei X; Song Y
    Oncotarget; 2017 Apr; 8(15):25469-25481. PubMed ID: 28424416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microenvironmental interactions and survival of CLL B-cells.
    Munk Pedersen I; Reed J
    Leuk Lymphoma; 2004 Dec; 45(12):2365-72. PubMed ID: 15621749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.